Lee HY, et al. RAS inhibitors-different responses to COVID-19

KJIM

| | Adjusted HR (95% CI) | *p* value |
|---|---|---|
| candesartan | 0.748 (0.343-1.634) | 0.467 |
| fimasartan | 0.159 (0.022-1.144) | 0.0677 |
| losartan | 1.082 (0.676-1.733) | 0.7419 |
| olmesartan | 1.046 (0.536-2.04) | 0.8952 |
| telmisartan | 1.484 (0.946-2.328) | 0.0859 |
| valsartan | 0.986 (0.618-1.573) | 0.9523 |
| others | 1.364 (0.549-3.392) | 0.5036 |

0.10   0.50  1.0  2.0  4.0

**Supplementary Figure 2.** Subgroup analysis for survival within 60 days by each angiotensin receptor blocker. Only individual drugs having sufficient prescription numbers for analysis were analyzed. HR, hazard ratio; CI, confidence interval.